Adenosine A2A and beta-2 adrenergic receptor agonists: Novel selective and synergistic multiple myeloma targets discovered through systematic combination screening

Richard J. Rickles, Winnie F. Tam, Thomas P. Giordano, Laura T. Pierce, Melissa Farwell, Douglas W. McMillin, Antoaneta Necheva, David Crowe, Mei Chen, William Avery, Vikram Kansra, Steffan T. Nawrocki, Jennifer S. Carew, Francis J. Giles, Constantine S. Mitsiades, Alexis A. Borisy, Kenneth C. Anderson, Margaret S. Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The use of combination drug regimens has dramatically improved the clinical outcome for patients with multiple myeloma. However, to date, combination treatments have been limited to approved drugs and a small number of emerging agents. Using a systematic approach to identify synergistic drug combinations, combination high-throughput screening (cHTS) technology, adenosine A2A and β-2 adrenergic receptor (β2AR) agonists were shown to be highly synergistic, selective, and novel agents that enhance glucocorticoid activity in B-cell malignancies. Unexpectedly, A2A and β2AR agonists also synergize with melphalan, lenalidomide, bortezomib, and doxorubicin. An analysis of agonists, in combination with dexamethasone or melphalan in 83 cell lines, reveals substantial activity in multiple myeloma and diffuse large B-cell lymphoma cell lines. Combination effects are also observed with dexamethasone as well as bortezomib, using multiple myeloma patient samples and mouse multiple myeloma xenograft assays. Our results provide compelling evidence in support of development of A2A and b2AR agonists for use in multi-drug combination therapy for multiple myeloma. Furthermore, use of cHTS for the discovery and evaluation ofnew targets and combination therapies has the potential to improve cancer treatment paradigms and patient outcomes.

Original languageEnglish (US)
Pages (from-to)1432-1442
Number of pages11
JournalMolecular Cancer Therapeutics
Volume11
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Adrenergic beta-2 Receptor Agonists
Multiple Myeloma
Adenosine
Adrenergic Agonists
Melphalan
Drug Combinations
Dexamethasone
Cell Line
Lymphoma, Large B-Cell, Diffuse
Combination Drug Therapy
Heterografts
Doxorubicin
Glucocorticoids
Neoplasms
B-Lymphocytes
Therapeutics
Technology
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adenosine A2A and beta-2 adrenergic receptor agonists : Novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. / Rickles, Richard J.; Tam, Winnie F.; Giordano, Thomas P.; Pierce, Laura T.; Farwell, Melissa; McMillin, Douglas W.; Necheva, Antoaneta; Crowe, David; Chen, Mei; Avery, William; Kansra, Vikram; Nawrocki, Steffan T.; Carew, Jennifer S.; Giles, Francis J.; Mitsiades, Constantine S.; Borisy, Alexis A.; Anderson, Kenneth C.; Lee, Margaret S.

In: Molecular Cancer Therapeutics, Vol. 11, No. 7, 07.2012, p. 1432-1442.

Research output: Contribution to journalArticle

Rickles, RJ, Tam, WF, Giordano, TP, Pierce, LT, Farwell, M, McMillin, DW, Necheva, A, Crowe, D, Chen, M, Avery, W, Kansra, V, Nawrocki, ST, Carew, JS, Giles, FJ, Mitsiades, CS, Borisy, AA, Anderson, KC & Lee, MS 2012, 'Adenosine A2A and beta-2 adrenergic receptor agonists: Novel selective and synergistic multiple myeloma targets discovered through systematic combination screening', Molecular Cancer Therapeutics, vol. 11, no. 7, pp. 1432-1442. https://doi.org/10.1158/1535-7163.MCT-11-0925
Rickles, Richard J. ; Tam, Winnie F. ; Giordano, Thomas P. ; Pierce, Laura T. ; Farwell, Melissa ; McMillin, Douglas W. ; Necheva, Antoaneta ; Crowe, David ; Chen, Mei ; Avery, William ; Kansra, Vikram ; Nawrocki, Steffan T. ; Carew, Jennifer S. ; Giles, Francis J. ; Mitsiades, Constantine S. ; Borisy, Alexis A. ; Anderson, Kenneth C. ; Lee, Margaret S. / Adenosine A2A and beta-2 adrenergic receptor agonists : Novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. In: Molecular Cancer Therapeutics. 2012 ; Vol. 11, No. 7. pp. 1432-1442.
@article{297ccad8e26a4b2baf5122283778163d,
title = "Adenosine A2A and beta-2 adrenergic receptor agonists: Novel selective and synergistic multiple myeloma targets discovered through systematic combination screening",
abstract = "The use of combination drug regimens has dramatically improved the clinical outcome for patients with multiple myeloma. However, to date, combination treatments have been limited to approved drugs and a small number of emerging agents. Using a systematic approach to identify synergistic drug combinations, combination high-throughput screening (cHTS) technology, adenosine A2A and β-2 adrenergic receptor (β2AR) agonists were shown to be highly synergistic, selective, and novel agents that enhance glucocorticoid activity in B-cell malignancies. Unexpectedly, A2A and β2AR agonists also synergize with melphalan, lenalidomide, bortezomib, and doxorubicin. An analysis of agonists, in combination with dexamethasone or melphalan in 83 cell lines, reveals substantial activity in multiple myeloma and diffuse large B-cell lymphoma cell lines. Combination effects are also observed with dexamethasone as well as bortezomib, using multiple myeloma patient samples and mouse multiple myeloma xenograft assays. Our results provide compelling evidence in support of development of A2A and b2AR agonists for use in multi-drug combination therapy for multiple myeloma. Furthermore, use of cHTS for the discovery and evaluation ofnew targets and combination therapies has the potential to improve cancer treatment paradigms and patient outcomes.",
author = "Rickles, {Richard J.} and Tam, {Winnie F.} and Giordano, {Thomas P.} and Pierce, {Laura T.} and Melissa Farwell and McMillin, {Douglas W.} and Antoaneta Necheva and David Crowe and Mei Chen and William Avery and Vikram Kansra and Nawrocki, {Steffan T.} and Carew, {Jennifer S.} and Giles, {Francis J.} and Mitsiades, {Constantine S.} and Borisy, {Alexis A.} and Anderson, {Kenneth C.} and Lee, {Margaret S.}",
year = "2012",
month = "7",
doi = "10.1158/1535-7163.MCT-11-0925",
language = "English (US)",
volume = "11",
pages = "1432--1442",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Adenosine A2A and beta-2 adrenergic receptor agonists

T2 - Novel selective and synergistic multiple myeloma targets discovered through systematic combination screening

AU - Rickles, Richard J.

AU - Tam, Winnie F.

AU - Giordano, Thomas P.

AU - Pierce, Laura T.

AU - Farwell, Melissa

AU - McMillin, Douglas W.

AU - Necheva, Antoaneta

AU - Crowe, David

AU - Chen, Mei

AU - Avery, William

AU - Kansra, Vikram

AU - Nawrocki, Steffan T.

AU - Carew, Jennifer S.

AU - Giles, Francis J.

AU - Mitsiades, Constantine S.

AU - Borisy, Alexis A.

AU - Anderson, Kenneth C.

AU - Lee, Margaret S.

PY - 2012/7

Y1 - 2012/7

N2 - The use of combination drug regimens has dramatically improved the clinical outcome for patients with multiple myeloma. However, to date, combination treatments have been limited to approved drugs and a small number of emerging agents. Using a systematic approach to identify synergistic drug combinations, combination high-throughput screening (cHTS) technology, adenosine A2A and β-2 adrenergic receptor (β2AR) agonists were shown to be highly synergistic, selective, and novel agents that enhance glucocorticoid activity in B-cell malignancies. Unexpectedly, A2A and β2AR agonists also synergize with melphalan, lenalidomide, bortezomib, and doxorubicin. An analysis of agonists, in combination with dexamethasone or melphalan in 83 cell lines, reveals substantial activity in multiple myeloma and diffuse large B-cell lymphoma cell lines. Combination effects are also observed with dexamethasone as well as bortezomib, using multiple myeloma patient samples and mouse multiple myeloma xenograft assays. Our results provide compelling evidence in support of development of A2A and b2AR agonists for use in multi-drug combination therapy for multiple myeloma. Furthermore, use of cHTS for the discovery and evaluation ofnew targets and combination therapies has the potential to improve cancer treatment paradigms and patient outcomes.

AB - The use of combination drug regimens has dramatically improved the clinical outcome for patients with multiple myeloma. However, to date, combination treatments have been limited to approved drugs and a small number of emerging agents. Using a systematic approach to identify synergistic drug combinations, combination high-throughput screening (cHTS) technology, adenosine A2A and β-2 adrenergic receptor (β2AR) agonists were shown to be highly synergistic, selective, and novel agents that enhance glucocorticoid activity in B-cell malignancies. Unexpectedly, A2A and β2AR agonists also synergize with melphalan, lenalidomide, bortezomib, and doxorubicin. An analysis of agonists, in combination with dexamethasone or melphalan in 83 cell lines, reveals substantial activity in multiple myeloma and diffuse large B-cell lymphoma cell lines. Combination effects are also observed with dexamethasone as well as bortezomib, using multiple myeloma patient samples and mouse multiple myeloma xenograft assays. Our results provide compelling evidence in support of development of A2A and b2AR agonists for use in multi-drug combination therapy for multiple myeloma. Furthermore, use of cHTS for the discovery and evaluation ofnew targets and combination therapies has the potential to improve cancer treatment paradigms and patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84863803075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863803075&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-11-0925

DO - 10.1158/1535-7163.MCT-11-0925

M3 - Article

C2 - 22474168

AN - SCOPUS:84863803075

VL - 11

SP - 1432

EP - 1442

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 7

ER -